Company profile
Cytek Biosciences, Inc.
NASDAQ: CTKB · Healthcare · Medical - Devices
#290 of 1,422 Healthcare companies by revenue43rd-percentile growth
EA Score
58CFH 62DQ 52GM 58SS 59
v0.1 · 65/100 weight · provisional
↑ workforce scale, Altman-Z · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$204.2M
Rev growth YoY (TTM)
+3.6%
Net income (FY)
-$66.5M
Employees
682
as of 2026-08-11
Market cap
$601.8M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$201.5M$201.5M2025
Net income-$66.5M-$66.5M2025
Operating income-$40.4M-$40.4M2025
Total assets$461.5M$461.5M2025
Liabilities$119.8M$119.8M2025
Equity$341.7M$341.7M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product72%
Service28%
By geography
UNITED STATES47%
EMEA28%
Asia Pacific20%
Other5%
The read
What is Cytek Biosciences, Inc.’s revenue?
Cytek Biosciences, Inc. booked $201.5M in FY2025 revenue, growing 0.5% year over year — about the middle of the pack among Healthcare companies we track, at a -33.0% net margin.
Peers · Healthcare
Treace Medical Concepts, Inc.55CEstablishment Labs Holdings Inc.59CCanopy Growth Corporation59CSI-BONE, Inc.70BStrata Critical Medical, Inc.60CLifeMD, Inc.73BNeighbors
Alameda →Key facts
CEOWenbin Jiang
SectorHealthcare
IndustryMedical - Devices
HeadquartersFremont, CA
ExchangeNASDAQ: CTKB
Employees682
IPO date2021-07-23
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.